Informations:
Erreur:
ID
18993
Description
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193232
Lien
https://clinicaltrials.gov/show/NCT00193232
Mots-clés
Versions (1)
- 29/11/2016 29/11/2016 -
Téléchargé le
29 novembre 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Prostate Cancer NCT00193232
Eligibility Prostate Cancer NCT00193232
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00193232
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Prostate carcinoma | Neoplasm Metastasis Evidence of
Item
prostate cancer, and objective evidence of metastatic disease
boolean
C0600139 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0332120 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,1])
C0332120 (UMLS CUI [2,2])
androgen suppression | Disease Progression
Item
progression while receiving androgen ablation therapy
boolean
C1515985 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0242656 (UMLS CUI [2])
Chemotherapy
Item
no previous chemotherapy
boolean
C0392920 (UMLS CUI [1])
Measurable Disease | Evaluable Disease | Serum Prostate Specific Antigen Increased
Item
measurable or evaluable disease in conjunction with elevated serum psa levels
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
C1883014 (UMLS CUI [3])
C1516986 (UMLS CUI [2])
C1883014 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Bone Marrow function | Liver function | Renal function
Item
adequate bone marrow, liver and kidney function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Informed Consent
Item
voluntarily provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Clinical Trial Eligibility Criteria Fulfill
Item
you cannot participate in this study if any of the following apply to you:
boolean
C1516637 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Peripheral Neuropathy Moderate | Peripheral Neuropathy Severe
Item
moderate or severe peripheral neuropathy
boolean
C0031117 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C0031117 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0205081 (UMLS CUI [1,2])
C0031117 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Age
Item
age < 18 years
boolean
C0001779 (UMLS CUI [1])
Medical condition Serious Interferes with Protocol Therapeutic procedure
Item
other serious medical conditions that may interfere with protocol therapy
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348563 (UMLS CUI [1,4])
C0087111 (UMLS CUI [1,5])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348563 (UMLS CUI [1,4])
C0087111 (UMLS CUI [1,5])
Malignant Neoplasms
Item
other active malignancies
boolean
C0006826 (UMLS CUI [1])
Therapeutic procedure Invasive cancer
Item
history of treatment for other invasive cancers within 3 years
boolean
C0087111 (UMLS CUI [1,1])
C0677898 (UMLS CUI [1,2])
C0677898 (UMLS CUI [1,2])
Clinical Trial Eligibility Criteria Additional
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])